Clinical Trials Logo

Filter by:
NCT ID: NCT06450171 Not yet recruiting - Clinical trials for Predisposition, Genetic

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

Start date: December 2024
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test

NCT ID: NCT06450041 Not yet recruiting - Neuroblastoma Clinical Trials

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.

NCT ID: NCT06449638 Not yet recruiting - Diabetic Foot Clinical Trials

Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs

CAMPSTIM
Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of four dehydrated complete human placental membrane, also defined as Cellular, Acellular, Matrix-like Products/skin substitutes, plus SOC versus SOC alone in achieving complete closure of hard-to-heal diabetic foot ulcers over 12 weeks using a modified platform trial design.

NCT ID: NCT06449326 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorder

Multimodal Image Analysis and Guidance of Neuromodulation for Trauma-Related Symptoms

MAGNETS
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

MAGNETS is a prospective, randomized, parallel-design, sham-controlled clinical trial of accelerated, functional magnetic resonance imaging (fMRI)-guided intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (dlPFC) for chronic symptoms of posttraumatic stress disorder (PTSD) in a comorbid Veteran population.

NCT ID: NCT06449313 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer

NEO-SURG
Start date: September 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial] is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage III non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node involvement.. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.

NCT ID: NCT06448780 Not yet recruiting - Clinical trials for Hypoxic-Ischemic Encephalopathy

Dose Optimization of Caffeine for HIE

Start date: November 2024
Phase: Phase 1
Study type: Interventional

This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.

NCT ID: NCT06448546 Not yet recruiting - Huntington Disease Clinical Trials

Gut Microbiomes in HD

Start date: June 2024
Phase:
Study type: Observational

The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease. The investigators are trying to determine if patients who are diagnosed with adult-onset HD and who exhibit a rapid rate of disease progression have unique populations of bacteria in their gut as compared to patients with slower progression.

NCT ID: NCT06448286 Not yet recruiting - Glioblastoma Clinical Trials

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and tumor tissue. CEST MRI is a technique that uses differences in the tissue environment, like protein concentration or intracellular pH, to generate contrast differences. CEST MRI may identify tumor tissue that does not enhance with standard of care MRI. PH weighted CEST MRI based surgical resection may be more effective compared to standard of care surgical resection in treating patients with glioblastoma.

NCT ID: NCT06448039 Not yet recruiting - Clinical trials for Chronic Tympanic Membrane Perforation

In-office Repair of Chronic Tympanic Membrane Perforations

Start date: June 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to compare the application of fibroblast growth factor 2 (FGF2) with normal saline for the healing of chronic tympanic membrane (TM) perforations. This is an extension of a prior study. The main question it aims to answer is: Will modifications to our prior surgical trial provide higher success rates in obtaining complete closure of chronic tympanic membrane perforations? Twenty participants will be randomized in a controlled study to FGF2 or saline in a 3:1 ratio and the total tympanic membrane closure compared.

NCT ID: NCT06448026 Not yet recruiting - Clinical trials for Locally Recurrent OCSCC

A Phase 2 Study to Evaluate the Efficacy of the Combination of Cemiplimab and Cetuximab Prior to Salvage Surgery in Patients With Locally Recurrent (Stage 3-5) OCSCC

Start date: November 29, 2024
Phase: Phase 2
Study type: Interventional

To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent OCSCC.